Obesity is a major growing health concern around the world. In most markets, a person is considered obese if their Body Mass Index (BMI) exceeds 30 kilograms per square meter (kg/m2), calculated by dividing body mass in kilograms by height in meters squared. With the global prevalence continuing to rise, the disease has placed significant burden on healthcare expenditure, as it is also a major risk factor for cardiovascular diseases, diabetes and cancer.
Anti-obesity pharmacotherapy can be used as an adjunct lifestyle modification to improve weight loss in order to significantly reduce obesity-associated health risks in obese patients. However, the use of currently available anti-obesity drugs is largely limited by poor long-term safety and a modest weight loss effect. Despite substantial clinical and regulatory challenges, the early-stage obesity pipeline remains robust, containing a high level of first-in-class innovation that has the potential to be translated into effective and safe weight loss treatments.
Full Report Details at
Historically, the obesity market has suffered from long-term safety concerns and modest efficacy with current treatments, both of which contribute to the low prescription rate and limited widespread use.
* What are the main safety concerns that lead to significant challenges in gaining drug approval in obesity?
* Why is sustainable weight loss difficult to achieve, and what is the implication for future drug development?
Analysis reveals a high level of innovation and diversity in the pipeline, with 75 first-in-class programs identified to act on 60 unique molecular targets.
* What is the dominant target family across these first-in-class pipeline products?
* How well do they align with the underlying signaling pathways governing the central and peripheral regulation of food intake, and energy expenditure?
Some first-in-class targets are deemed more likely to be developed into marketable treatments than others, having demonstrated substantial body weight reduction in Preclinical studies and addressing multiple mechanisms underpinning the development of obesity.
* What is the scientific rationale behind these targets? How are they likely to surpass existing treatment?
* Apart from body weight change, what other parameters are commonly used to measure the effect of investigational therapies?
Deals involving first-in-class obesity products are more likely to be made in earlier stages of development than non-first-in-class deals, supported by industry-wide analysis.
* What is the dominant molecular target in the obesity deals landscape?
* What are the promising first-in-class products still available for future licensing?
Reasons to Get this Report
This report will allow you to -
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.
For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)
You may also be interested in these related reports:
- Frontier Pharma: Versatile Innovation in Oncology - Identifying and Commercializing Versatile First-in-Class Innovation
- Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Pain - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
- Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation
"Frontier Pharma: Obesity - Identifying and Commercializing First-in-Class Innovation" Published
Contact Name: Bill Thompson
Contact Email: firstname.lastname@example.org
Contact Phone: 1-413-485-7001